Acceleron Announces Presentation of New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia

Acceleron Pharma (NASDAQ: XLRN today announced that data in five abstracts for sotatercept and ACE-536, Acceleron's programs to treat red blood cell disorders, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10th at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a See full press release